Tipiracil and Trifluridine Are Powerful Opponents Against Colorectal Cancer

Tipiracil and Trifluridine Are Powerful Opponents Against Colorectal CancerPositive findings were recently revealed from Taiho Oncology Inc. with the revelation of their global Phase 3 trial coined RECOURSE. This extensive trial was of the anticancer combination duo Tipiracil and Trifluridine, also called TAS-102. Data disseminated from this Phase 3 trial demonstrated that TAS-102 reduced the risk of mortality for patients with unresectable colon cancer by 32 percent as compared to a placebo. Clinical trial participants also achieved statistically sizable improvements in progression free and overall survival, including patients who were previously intolerant to former therapies. This inspiring data was presented at the European Society for Medical Oncology 16th World Congress on Gastrointestinal Cancer, which was held in Barcelona, Spain.

The RECOURSE trial included 800 patients that were randomized to receive best in care treatments either with or without the formidable TAS-102 combination treatment. All of the patients enrolled in this Phase 3 trial had completed on average two previous therapies which were deemed unsuccessful. Both the primary outcome measure of increased overall survival and secondary endpoint of progression-free survival were met.

The patient group who were administered Tipiracil and Trifluridine { TAS-102} gained an overall survival time of 7.1 months, as well as a 52 percent decrease in the risk of disease progression as compared to the placebo arm of the study. Clinically relevant results from the dynamic duo Tipiracil and Trifluridine clearly offered patients with refractory metastatic colon cancer a viable chance at extended survival. As efficacious antitumor agents both Tipiracil and Trifluridine have proven tolerable for and safe for patients in studies. Adverse effects were reported, but there were no participants who withdrew due to these effects. Most commonly reported side effects included diarrhea, anemia, leukopenia, vomiting, nausea, neutropenia and fatigue.

Colorectal Cancer Statistics

Colorectal cancer is the third most common cancer for American men and women. The American Cancer Society offers daunting statistics estimating that the lifetime risk of developing this potentially fatal disease is 1 in 20 people in the U.S. Approximately 96,830 new cases of colon cancer are diagnosed each year in the United States, along with roughly 40,000 new cases of rectal cancer. Estimates regarding the mortality of patients diagnosed with colon cancer are of great concern as well, with an estimated 50,310 fatalities predicted in 2014. Novel treatments which improve overall survival and extend progression free survival are critically necessary.

LGM Pharma is a provider of Trifluridine, CAS# 70-00-8, and Tipiracil, CAS# 183204-74-2 APIs for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: